ArticleACS applied materials & interfaces2017
CuS-Based Theranostic Micelles for NIR-Controlled Combination Chemotherapy and Photothermal Therapy and Photoacoustic Imaging.
Article in ACS applied materials & interfaces, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 82 citations in OpenAlex.
- NIR-II-triggered copper single-atom catalyst depots coupling catalysis and drug release for infected chronic wounds with dysregulated inflammation.Materials today. Bio · 2026Article
- Photothermal Coating on Zinc Alloy for Controlled Biodegradation and Improved Osseointegration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Iron-fueled ferroptosis: a new axis for immunomodulation to overcome cancer drug resistance-from immune microenvironment crosstalk to therapeutic translation.Frontiers in immunology · 2025Review
- Light-Responsive Nanoantennas Integrated into Nanoscale Metal-Organic Frameworks for Photothermal Drug Delivery.Small science · 2024Article
- Stimuli-responsive peptide assemblies: Design, self-assembly, modulation, and biomedical applications.Bioactive materials · 2024Review
- Recent Progress of Copper-Based Nanomaterials in Tumor-Targeted Photothermal Therapy/Photodynamic Therapy.Pharmaceutics · 2023Review
- Isocorrole-Loaded Polymer Nanoparticles for Photothermal Therapy under 980 nm Light Excitation.ACS omega · 2022Article
- Carrier-free nanoparticles of camptothecin prodrug for chemo-photothermal therapy: the making, in vitro and in vivo testing.Journal of nanobiotechnology · 2021Article
- Near-infrared light triggered activation of pro-drug combination cancer therapy and induction of immunogenic cell death.International journal of pharmaceutics · 2021Article
- Synthesis of iridium-based nanocomposite with catalase activity for cancer phototherapy.Journal of nanobiotechnology · 2021Article
- Semiconducting polymer nanoparticles for photothermal ablation of colorectal cancer organoids.Scientific reports · 2021Article
- Kinetics of Nanomedicine in Tumor Spheroid as anFrontiers in bioengineering and biotechnology · 2021Review
- The Coppery Age: Copper (Cu)-Involved Nanotheranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- CuS@PDA-FA nanocomposites: a dual stimuli-responsive DOX delivery vehicle with ultrahigh loading level for synergistic photothermal-chemotherapies on breast cancer.Journal of materials chemistry. B · 2020Article
- Biconcave Carbon Nanodisks for Enhanced Drug Accumulation and Chemo-Photothermal Tumor Therapy.Advanced healthcare materials · 2019Article
- Thermo-Sensitive Nanomaterials: Recent Advance in Synthesis and Biomedical Applications.Nanomaterials (Basel, Switzerland) · 2018Review
- NIR-induced spatiotemporally controlled gene silencing by upconversion nanoparticle-based siRNA nanocarrier.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Porous MnFeRSC advances · 2018Article
- A review on core-shell structured unimolecular nanoparticles for biomedical applications.Advanced drug delivery reviews · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Cancer remains a major threat to human health due to low therapeutic efficacies of currently available cancer treatment options. Nanotheranostics, capable of simultaneous therapy and diagnosis/monitoring of diseases, has attracted increasing amounts of attention, particularly for cancer treatment. In this study, CuS-based theranostic micelles capable of simultaneous combination chemotherapy and photothermal therapy (PTT), as well as photoacoustic imaging, were developed for targeted cancer therapy. The micelle was formed by a CuS nanoparticle (NP) functionalized by thermosensitive amphiphilic poly(acrylamide-acrylonitrile)-poly(ethylene glycol) block copolymers. CuS NPs under near-infrared (NIR) irradiation induced a significant temperature elevation, thereby enabling NIR-triggered PTT. Moreover, the hydrophobic core formed by poly(acrylamide-acrylonitrile) segments used for drug encapsulation exhibited an upper critical solution temperature (UCST; ∼38 °C), which underwent a hydrophobic-to-hydrophilic transition once the temperature rose above the UCST induced by NIR-irradiated CuS NPs, thereby triggering a rapid drug release and enabling NIR-controlled chemotherapy. The CuS-based micelles conjugated with GE11 peptides were tested in an epidermal growth factor receptor-overexpressing triple-negative breast cancer model. In both two-dimensional monolayer cell and three-dimensional multicellular tumor spheroid models, GE11-tagged CuS-based micelles under NIR irradiation, enabling the combination chemotherapy and PTT, exhibited the best therapeutic outcome due to a synergistic effect. These CuS-based micelles also displayed a good photoacoustic imaging ability under NIR illumination. Taken together, this multifunctional CuS-based micelle could be a promising nanoplatform for targeted cancer nanotheranostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.